Physician profile
Jonas Leibowitz
NPI 1316038326
$613,050.19
in general payments reported to CMS, 2019-2025
59 companies · $79K in 2025
The $79K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99K · 2020: $55K · 2021: $77K · 2022: $133K · 2023: $67K · 2024: $103K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $213K · Food and Beverage: $17K · Travel and Lodging: $17K · Consulting Fee: $1,820 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $213,165.62 |
| Food and Beverage | $16,896.05 |
| Travel and Lodging | $16,549.75 |
| Consulting Fee | $1,820.00 |
| Education | $212.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $258,396.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $232,190.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $32,200.14 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31,721.58 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $21,688.94 | 2019-2023 | Steglatro |
| Corcept Therapeutics | $8,210.36 | 2019-2025 | Korlym |
| Abbvie INC. | $6,754.16 | 2019-2025 | |
| Gilead Sciences, INC. | $3,493.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $2,758.58 | 2019-2020 | |
| Medtronic, INC. | $2,207.60 | 2021-2024 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Medtronic Minimed, INC. | $1,834.16 | 2019 | |
| Antares Pharma, INC. | $1,493.04 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $1,074.54 | 2019-2025 | |
| Amgen INC. | $969.37 | 2019-2025 | Evenity, Prolia, Tepezza |
| Mannkind Corporation | $966.30 | 2019-2025 | Afrezza |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $816.09 | 2019-2025 | Tymlos, Binosto |
| Currax Pharmaceuticals LLC | $622.29 | 2019-2025 | Contrave, Nexletol, Nexlizet |
| Abbott Laboratories | $551.54 | 2019-2025 | Freestyle Libre |
| Dexcom, INC. | $380.87 | 2020-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.07 | 2019-2024 | Cycloset |
| Ibsa Pharma INC. | $335.38 | 2019-2024 | Tirosint, Licart, Tirosint |
| Amneal Pharmaceuticals LLC | $308.14 | 2021-2024 | Unithroid |
| Horizon Therapeutics Plc | $262.48 | 2020-2023 | Tepezza |
| Pfizer INC. | $254.95 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $240.54 | 2024-2025 | Recorlev |
| Alexion Pharmaceuticals, INC. | $209.68 | 2019-2025 | Strensiq |
| Verity Pharmaceuticals INC. | $203.69 | 2024-2025 | Tlando, Trelstar |
| Madrigal Pharmaceuticals | $202.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Intra-Sana Laboratories | $200.30 | 2023-2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Lifescan, INC. | $199.27 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $170.42 | 2019-2020 | |
| Becton, Dickinson and Company | $168.21 | 2019-2022 | |
| Insulet Corporation | $134.20 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $120.40 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $114.79 | 2021-2025 | Isturisa, Signifor Lar |
| Astellas Pharma US INC | $109.79 | 2023 | Veozah |
| Amarin Pharma, INC. | $105.23 | 2019-2020 | |
| Halozyme INC | $102.35 | 2023 | |
| Esperion Therapeutics, INC. | $91.02 | 2021-2023 | Nexletol |
| Amryt Pharma Holdings Ltd | $73.87 | 2022-2023 | Mycapssa |
| Vivus LLC | $70.40 | 2019-2021 | |
| Valeritas, INC. | $68.60 | 2019 | |
| Acerus Pharmaceuticals Corporation | $67.67 | 2021 | |
| Ascendis Pharma Endocrinology INC | $62.71 | 2024-2025 | Yorvipath |
| Intuity Medical INC | $56.34 | 2022 | |
| Clarus Therapeutics INC. | $55.50 | 2021 | |
| Azurity Pharmaceuticals, INC. | $55.19 | 2023 | Adthyza |
| Tandem Diabetes Care, INC. | $52.65 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $49.26 | 2020 | |
| Cequr Corporation | $39.74 | 2022-2023 | Cequr Simplicity |
| Embecta Corp. | $37.83 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Eusa Pharma (US) LLC | $24.55 | 2022 | |
| Exact Sciences Corporation | $23.00 | 2023 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $21.34 | 2025 | |
| Acella Pharmaceuticals, LLC | $19.83 | 2025 | NP Thyroid 60 |
| Eisai INC. | $18.20 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $17.29 | 2025 | Imcivree |
| Seqirus USA INC | $13.48 | 2024 | Fluad, Flucelvax |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonas Leibowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.